BeOne Medicines stock gained 1.00 percent on October 5 as targets rose

Published on 10/07/2026 at 03:44 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

BeOne Medicines stock had a consensus Buy from 17 analysts, with an average USD 402.71 target. Q2 revenue reached USD 1.71 billion and earnings per share USD 2.05.

ONC, US07725L1026, Illustration mit AI erstellt.

BeOne Medicines stock (ISIN US07725L1026) gained 1.00 percent to USD 361.65 on Nasdaq on October 5, 2026, giving the oncology company a market capitalization of USD 38.7 billion. The move followed a fresh round of analyst commentary, including a higher JPMorgan target.

JPMorgan raises its target

According to Markets Insider on October 1, 2026, JPMorgan analyst Jessica Fye raised the price target to USD 445 from USD 425 and maintained an Overweight rating. The note cited the continued sales trajectory of BRUKINSA ahead of BeOne Medicines' third quarter report.

The company enters that report cycle after a strong second quarter. MarketBeat reported that second quarter 2026 earnings per share reached USD 2.05, above the USD 1.40 consensus, while revenue was USD 1.71 billion against USD 1.66 billion expected.

Revenue and profit set the bar

The quarterly figures make execution the central test for the next update. Revenue exceeded consensus by USD 50 million, while earnings per share beat estimates by USD 0.65, giving investors two measurable benchmarks for the November report.

BeOne Medicines also reported second quarter net income of USD 237.0 million and a 14.0 percent net margin, according to Simply Wall St. That combination of revenue growth and profitability has supported the higher valuation, but it also raises the performance threshold for upcoming clinical and commercial updates.

Consensus target stays above Nasdaq price

MarketBeat listed a Buy consensus from 17 analysts and an average 12-month target of USD 402.71. That target stands 11.4 percent above the USD 361.65 Nasdaq price on October 5, 2026, while the published one-year range was USD 253.95 to USD 385.22.

Simply Wall St lists November 10, 2026, as the date for BeOne Medicines to report third quarter results. The date gives the market a defined checkpoint for revenue, earnings and pipeline execution.

Stock remains below its yearly high

BeOne Medicines stock was last at USD 361.65 on Nasdaq on October 5, 2026, at 4:00 p.m. ET, after rising USD 3.58 on the session. The price remained below the 52-week high of USD 385.22, leaving the next results release as the clearest scheduled test of the valuation.